NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its quarterly earnings results on Monday, November, 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.14 by $0.03. The biotechnology company earned $43.29 million during the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

7 brokers have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $50.00 to $83.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $72.80 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

News headlines about ARWR stock have been trending very positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 3.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 11,120,000 shares, a decline of 8.9% from the December 15th total of 12,200,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is presently 4.9 days. Approximately 11.9% of the company's shares are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF) and Catalent (CTLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Sarepta Therapeutics (SRPT), AbbVie (ABBV), salesforce.com (CRM), Advanced Micro Devices (AMD), Paypal (PYPL) and Bank of America (BAC).

Arrowhead Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.02%), IFP Advisors Inc (0.01%), Nisa Investment Advisors LLC (0.01%), Assenagon Asset Management S.A. (0.01%) and Calamos Advisors LLC (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Louisiana State Employees Retirement System, Calamos Advisors LLC and IFP Advisors Inc. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Assenagon Asset Management S.A. and Wedbush Securities Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $56.42.

Arrowhead Pharmaceuticals has a market capitalization of $5.40 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]